Oligonucleotide non-viral delivery systems

A - Human Necessities – 61 – K

Patent

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

A61K 48/00 (2006.01) C12N 15/87 (2006.01)

Patent

CA 2662560

Low molecular weight low molecular weight chitosan oligomers were able to self- assemble siRNA into nanosized particles, provide protection against enzymatic degradation, and mediate gene silencing that is stable over a long period of time in vitro. The control of structural variables in formulating complexes of siRNA with low molecular weight chitosans provides an efficient alternative delivery system for siRNA in vitro and in vivo.

L'invention concerne des oligomères de chitosane de faible poids moléculaire, qui peuvent induire l'auto-assemblage de l'ARNsi en nanoparticules, fournir une protection contre la dégradation enzymatique, et induire un silençage génique in vitro stable pendant une longue durée. La régulation de variables structurelles dans la formulation de complexes d'ARNsi comprenant des chitosanes de faible poids moléculaire fournit, in vitro et in vivo, un système d'apport substitutif efficient pour l'ARNsi.

LandOfFree

Say what you really think

Search LandOfFree.com for Canadian inventors and patents. Rate them and share your experience with other people.

Rating

Oligonucleotide non-viral delivery systems does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Oligonucleotide non-viral delivery systems, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oligonucleotide non-viral delivery systems will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFCA-PAI-O-2009803

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.